Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

1.

The mTOR pathway in lung cancer and implications for therapy and biomarker analysis.

Ekman S, Wynes MW, Hirsch FR.

J Thorac Oncol. 2012 Jun;7(6):947-53. doi: 10.1097/JTO.0b013e31825581bd. Review.

PMID:
22588151
[PubMed - indexed for MEDLINE]
2.

[Mammalian target of rapamycin inhibitors for the targeted therapy of non-small cell lung cancer].

Lin Y, Zhang L.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2010 Apr;32(2):239-42. doi: 10.3881/j.issn.1000-503X.2010.02.025. Review. Chinese.

PMID:
20450558
[PubMed - indexed for MEDLINE]
Free Article
3.

LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer.

Han D, Li SJ, Zhu YT, Liu L, Li MX.

Asian Pac J Cancer Prev. 2013;14(7):4033-9. Review.

PMID:
23991948
[PubMed - indexed for MEDLINE]
Free Article
4.

Targeting the phosphatidylinosital 3-kinase, Akt, and mammalian target of rapamycin pathway in non-small cell lung cancer.

Cuffe S, Leighl NB.

J Thorac Oncol. 2011 Nov;6(11 Suppl 4):S1805-7. doi: 10.1097/01.JTO.0000407566.37523.c5. No abstract available.

PMID:
22005538
[PubMed - indexed for MEDLINE]
5.

mTOR signaling and drug development in cancer.

Dancey J.

Nat Rev Clin Oncol. 2010 Apr;7(4):209-19. doi: 10.1038/nrclinonc.2010.21. Epub 2010 Mar 16. Review.

PMID:
20234352
[PubMed - indexed for MEDLINE]
6.

The role of targeting mammalian target of rapamycin in lung cancer.

Pal SK, Figlin RA, Reckamp KL.

Clin Lung Cancer. 2008 Nov;9(6):340-5. doi: 10.3816/CLC.2008.n.049. Review.

PMID:
19073516
[PubMed - indexed for MEDLINE]
7.

Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer.

Papadimitrakopoulou V.

J Thorac Oncol. 2012 Aug;7(8):1315-26. doi: 10.1097/JTO.0b013e31825493eb. Review.

PMID:
22648207
[PubMed - indexed for MEDLINE]
8.

Targeting mTOR signaling pathway in ovarian cancer.

Mabuchi S, Hisamatsu T, Kimura T.

Curr Med Chem. 2011;18(19):2960-8. Review.

PMID:
21651485
[PubMed - indexed for MEDLINE]
9.

Phosphatidykinosital 3-kinase and mammalian target of rapamycin pathway in non-small-cell lung cancer.

Massarelli E, Papadimitrakopoulou VA.

J Thorac Oncol. 2012 Dec;7(16 Suppl 5):S379-82. doi: 10.1097/JTO.0b013e31826df0f0. Review. No abstract available.

PMID:
23160325
[PubMed - indexed for MEDLINE]
10.

Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.

Diaz-Padilla I, Duran I, Clarke BA, Oza AM.

Cancer Treat Rev. 2012 Oct;38(6):767-75. doi: 10.1016/j.ctrv.2012.02.001. Epub 2012 Feb 29. Review.

PMID:
22381585
[PubMed - indexed for MEDLINE]
11.

mTOR inhibitors in cancer therapy.

Zaytseva YY, Valentino JD, Gulhati P, Evers BM.

Cancer Lett. 2012 Jun 1;319(1):1-7. doi: 10.1016/j.canlet.2012.01.005. Epub 2012 Jan 17. Review.

PMID:
22261336
[PubMed - indexed for MEDLINE]
12.

mTOR kinase inhibitors as a treatment strategy in hematological malignancies.

Grzybowska-Izydorczyk O, Smolewski P.

Future Med Chem. 2012 Mar;4(4):487-504. doi: 10.4155/fmc.12.14. Review.

PMID:
22416776
[PubMed - indexed for MEDLINE]
13.

Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.

Nagata Y, Takahashi A, Ohnishi K, Ota I, Ohnishi T, Tojo T, Taniguchi S.

Int J Oncol. 2010 Oct;37(4):1001-10.

PMID:
20811722
[PubMed - indexed for MEDLINE]
14.

[mTOR inhibitor].

Muro K.

Gan To Kagaku Ryoho. 2011 Jan;38(1):7-11. Japanese.

PMID:
21368454
[PubMed - indexed for MEDLINE]
15.

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR.

Cancer Res. 2005 Aug 15;65(16):7052-8.

PMID:
16103051
[PubMed - indexed for MEDLINE]
Free Article
16.

GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.

Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L, Lesnick JD, Lewis C, Nonomiya J, Pang J, Salphati L, Olivero AG, Sutherlin DP, O'Brien C, Spoerke JM, Patel S, Lensun L, Kassees R, Ross L, Lackner MR, Sampath D, Belvin M, Friedman LS.

Mol Cancer Ther. 2011 Dec;10(12):2426-36. doi: 10.1158/1535-7163.MCT-11-0446. Epub 2011 Oct 13.

PMID:
21998291
[PubMed - indexed for MEDLINE]
Free Article
17.

mTOR inhibitors: facing new challenges ahead.

Mavrommati I, Maffucci T.

Curr Med Chem. 2011;18(18):2743-62. Review.

PMID:
21649581
[PubMed - indexed for MEDLINE]
18.

Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma.

Liu D, Huang Y, Chen B, Zeng J, Guo N, Zhang S, Liu L, Xu H, Mo X, Li W.

Cancer. 2011 Aug 15;117(16):3763-73. doi: 10.1002/cncr.25959. Epub 2011 Mar 8.

PMID:
21387259
[PubMed - indexed for MEDLINE]
Free Article
19.

Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.

Dobashi Y, Suzuki S, Kimura M, Matsubara H, Tsubochi H, Imoto I, Ooi A.

Hum Pathol. 2011 Feb;42(2):214-26. doi: 10.1016/j.humpath.2010.05.025. Epub 2010 Oct 30.

PMID:
21040950
[PubMed - indexed for MEDLINE]
20.

Recent clinical trials of mTOR-targeted cancer therapies.

Don AS, Zheng XF.

Rev Recent Clin Trials. 2011 Jan;6(1):24-35. Review.

PMID:
20868343
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk